Cephalon, Inc. Announces Agreement to Acquire Mepha AG (y 2)

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding the accretive nature of the acquisition of the Mepha Group with respect to Cephalon's adjusted earnings per share in 2010, anticipated scientific progress on its research programs, development of potential pharmaceutical products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, sales and earnings guidance, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.

    
    Contacts:
    US Media
    Sheryl Williams
    +1-610-738-6493
    swilliams@cephalon.com
    European Media
    Marie-Dominique de La Salle
    +33(1)49-81-82-48
    mddelasalle@cephalon.fr
    Investors
    Robert (Chip) Merritt
    +1-610-738-6376
    cmerritt@cephalon.com
    Linda Pavy
    Burson Marsteller
    +33(6)07-59-43-95
    Linda@Pavy@bm.com

US Media: Sheryl Williams, +1-610-738-6493, swilliams@cephalon.com; European Media: Marie-Dominique de La Salle, +33(1)49-81-82-48, mddelasalle@cephalon.fr; Investors: Robert (Chip) Merritt, +1-610-738-6376, cmerritt@cephalon.com; Linda Pavy: Burson Marsteller, +33(6)07-59-43-95, Linda@Pavy@bm.com